Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06340438
Other study ID # N-20240004 3rd subproject
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 27, 2024
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Aalborg University
Contact Silvia Lo Vecchio, PhD
Phone +4521397785
Email slv@hst.aau.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to investigate the relationship between different dimensions of catastrophizing (rumination, magnification, and helplessness) as well as some specific personality traits related to catastrophizing tendencies like anxiety sensitivity and fear sensitivity in the modulation of itch and pain intensities in an experimental setting.


Description:

Chronic itch severely affects the quality of life of patients by interfering with vital functions such as sleep, attention, and sexual activity, with an elevated expression of cognitive and emotional factors such as itch catastrophizing, worrying, as well as personality characteristics such as the predisposition to anxiety, depression, and suicidal thoughts that play an important role in the development, modification, and maintenance of itch. Moreover, chronic itch represents a significant socioeconomic burden due to a prevalence of around 10% in combination with largely suboptimal treatment since limited evidence has been found for the effectiveness of pharmaceutical interventions. The hypothesis of this project is that since it is well documented that the relationship between catastrophizing and pain and that itch and pain share many similarities, investigators can assume the existence of a similar connection between catastrophizing and itching.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy men and women - 18-60 years - Speak and understand English Exclusion Criteria: - Pregnancy or lactation - Drug addiction defined as any use of cannabis, opioids, or other addictive drugs - Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results - Lack of ability to cooperate - Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids - Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis) - Moles, scars, or tattoos in the area to be treated or tested. - Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain - Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Histamine
Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Cowhage
25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Aalborg University

Outcome

Type Measure Description Time frame Safety issue
Primary Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ). The Reinforcement Sensitivity Theory - Personality Questionnaire contains the following subscales: the Fight-Flight-Freeze System (FFFS, 10 items); the Behavioral Inhibition System (BIS, 23 items); and the Behavioral Approach System (BAS, 32 items). In total, 65 items have to be answered on a 4-point Likert-type scale ranging from 1 (not at all) to 4 (Highly). Baseline 1st session
Primary The Pittsburg Sleep Quality Index (PSQI) The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The seven component scores can be summarized in a global score ranging from zero to 21 with higher scores reflecting a worse overall quality of sleep. Baseline 1st session
Primary Depression, Anxiety, Stress Scale (DASS-21) The questionnaire measures the magnitude of depression, anxiety, and stress. Each of these three subscales consists of 7 questions answered using a 0-3 Likert scale, with 0 meaning "it did not apply to me", and 3 meaning "it applied to me very much" Baseline 1st session
Primary Positive And Negative Affect Schedule (PANAS) PANAS measures positive and negative affect dimensions. Positive affects (PA) are defined as "the extent to which a person feels active, enthusiastic, and alert". Negative affect (NA) is a condition of "general distress and unpleasable engagement". Baseline 1st session
Primary Pain Catastrophizing Scale (PCS). The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli. Thirteen items have to be answered on a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (all the time). 10 minutes after every itch induction on 1st session
Primary Itch Catastrophizing Scale (ICS). The ICS assesses negative and exaggerated coping concerning anticipated or experienced itchy stimuli. Thirteen items have to be answered on a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (all the time). 10 minutes after every itch induction on 1st session
Primary Learned Helplessness Scale (LHS) The questionnaire consists of 20 items, and the participant's response to each item is rated on a 4-point Likert scale ranging from strongly agree (1) to strongly disagree (4). 10 minutes after every itch induction on 1st session
Primary Positive And Negative Affect Schedule (PANAS) PANAS measures positive and negative affect dimensions. Positive affects (PA) are defined as "the extent to which a person feels active, enthusiastic, and alert". Negative affect (NA) is a condition of "general distress and unpleasable engagement". 10 minutes after every itch induction on 1st session
Primary Depression, Anxiety, Stress Scale (DASS-21) The questionnaire measures the magnitude of depression, anxiety, and stress. Each of these three subscales consists of 7 questions answered using a 0-3 Likert scale, with 0 meaning "it did not apply to me", and 3 meaning "it applied to me very much" Baseline 2nd session (3 days after 1st session)
Primary Positive And Negative Affect Schedule (PANAS) PANAS measures positive and negative affect dimensions. Positive affects (PA) are defined as "the extent to which a person feels active, enthusiastic, and alert". Negative affect (NA) is a condition of "general distress and unpleasable engagement" Baseline 2nd session (3 days after 1st session)
Primary Pain Catastrophizing Scale (PCS). The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli. Thirteen items have to be answered on a 5-point Likert-type scale. 10 minutes after every itch induction on 2nd session (3 days after 1st session)
Primary Itch Catastrophizing Scale (ICS). The ICS assesses negative and exaggerated coping concerning anticipated or experienced itchy stimuli. Thirteen items have to be answered on a 5-point Likert-type scale. 10 minutes after every itch induction on 2nd session (3 days after 1st session)
Primary Learned Helplessness Scale (LHS) The questionnaire consists of 20 items, and the participant's response to each item is rated on a 4-point Likert scale ranging from strongly agree (1) to strongly disagree (4). 10 minutes after every itch induction on 2nd session (3 days after 1st session)
Primary Positive And Negative Affect Schedule (PANAS) PANAS measures positive and negative affect dimensions. Positive affects (PA) are defined as "the extent to which a person feels active, enthusiastic, and alert". Negative affect (NA) is a condition of "general distress and unpleasable engagement" 10 minutes after every itch induction on 2nd session (3 days after 1st session)
Secondary Assessment of itch Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'. 1 minute after every itch inductions
Secondary Assessment of pain Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'. 1 minute after every itch inductions
See also
  Status Clinical Trial Phase
Recruiting NCT06152497 - The Role of Histamine in Muscle Protein Synthesis Following Resistance Training N/A
Recruiting NCT06081998 - Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity N/A
Not yet recruiting NCT06328543 - Itch Sensation Induced by Multiple Applications of Pruritogens (Temporal Summation) N/A
Completed NCT04672382 - Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine N/A
Completed NCT03576053 - A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing N/A
Recruiting NCT06081946 - Investigation of the Effects of Sleep Fragmentation on Itch and Pain Sensitivity N/A
Recruiting NCT06154824 - Repetitive Applications of Pruritogens and Effects of a Cutaneous-induced Pain Stimulation on Nonhistaminergic Itch Perception N/A
Completed NCT05131555 - Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle N/A
Recruiting NCT06328530 - Itch Sensation Induced by Simultaneous Application of Pruritogens (Spatial Summation) N/A